Dear Editor: We read with interest the retrospective study by Roldan et al. 1 assessing the
safety of oral anticoagulation in 201 patients with pulmonary arterial hypertension (PAH). It is …

Rationale: Pulmonary hypertension due to chronic lung disease (Group 3 PH) is a common
and highly morbid complication of chronic lung diseases with an associated one-year …

Inequity in health care is a multifaceted complex global issue not unique to rare disease.
Grouping countries into one unified entity is imperfect without a combined political‐strategic …

The Economic Burden of Pulmonary Hypertension Among Patients with Chronic Obstructive
Pulmonary Disease and Interstitial Lung Di Page 1 The Economic Burden of Pulmonary …

PURPOSE: Treatment guidelines recommend prostacyclin (PCY) therapies for the treatment
of pulmonary arterial hypertension (PAH) as initial or add-on therapy based upon a patients' …

Purpose Pulmonary hypertension (PH) is a heterogenous, often progressive disorder
leading to right heart failure and death. Previous analyses show stable PH mortality rates …

Older adults seen by primary care nurse practitioners (NPs) may have vague, atypical signs
and symptoms. Looking beyond the obvious diagnosis (sometimes hoofbeats are zebras …

RATIONALE: Pulmonary hypertension is a chronic progressive disorder characterized by
elevation in pulmonary artery pressure leading to right heart failure and death. Prior …

PROGRESSIVE AND ULTIMATELY fatal, pulmonary arterial hypertension (PAH) is a
disease of the pulmonary arterial vasculature with no known cause. In many patients, the …

Pulmonary hypertension (PH) occurs when the pulmonary vasculature is itself diseased or
becomes affected secondarily by comorbid conditions, commonly left heart or lung disease …